Michael Sweeney

1.4k total citations
35 papers, 884 citations indexed

About

Michael Sweeney is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Michael Sweeney has authored 35 papers receiving a total of 884 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Hematology. Recurrent topics in Michael Sweeney's work include Protein Degradation and Inhibitors (26 papers), Peptidase Inhibition and Analysis (7 papers) and Diabetes Treatment and Management (7 papers). Michael Sweeney is often cited by papers focused on Protein Degradation and Inhibitors (26 papers), Peptidase Inhibition and Analysis (7 papers) and Diabetes Treatment and Management (7 papers). Michael Sweeney collaborates with scholars based in United States, Australia and United Kingdom. Michael Sweeney's co-authors include Ewelina Kulikowski, Norman C.W. Wong, Jan O. Johansson, Stephen J. Nicholls, Kausik K. Ray, Gregory G. Schwartz, Kamyar Kalantar‐Zadeh, Sylwia Wasiak, Dean Gilham and Laura Tsujikawa and has published in prestigious journals such as JAMA, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Sweeney

35 papers receiving 832 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Sweeney United States	16	585	161	145	142	112	35	884
Ewelina Kulikowski United States	19	771 1.3×	186 1.2×	214 1.5×	169 1.2×	159 1.4×	49	1.2k
Jeanette Hamlington United States	11	324 0.6×	66 0.4×	135 0.9×	130 0.9×	26 0.2×	14	773
Bogusz Trojanowicz Germany	17	304 0.5×	73 0.5×	62 0.4×	100 0.7×	81 0.7×	38	716
Kenji Sakakibara Japan	17	257 0.4×	40 0.2×	87 0.6×	101 0.7×	79 0.7×	51	771
Stefanie Tippmer Germany	9	271 0.5×	89 0.6×	42 0.3×	90 0.6×	166 1.5×	12	648
Daniel R. Jacobson United States	15	965 1.6×	74 0.5×	77 0.5×	123 0.9×	296 2.6×	31	1.2k
Mette L. Johansen United States	12	195 0.3×	92 0.6×	68 0.5×	78 0.5×	23 0.2×	18	671
Vreni Schneider Switzerland	11	357 0.6×	45 0.3×	19 0.1×	136 1.0×	51 0.5×	13	952
Mustafa Yalçınkaya United States	13	243 0.4×	58 0.4×	69 0.5×	140 1.0×	27 0.2×	22	579
Susanne Rolle Germany	13	226 0.4×	35 0.2×	42 0.3×	61 0.4×	44 0.4×	16	638

Countries citing papers authored by Michael Sweeney

Since Specialization

Citations

This map shows the geographic impact of Michael Sweeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Sweeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Sweeney more than expected).

Fields of papers citing papers by Michael Sweeney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Sweeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Sweeney. The network helps show where Michael Sweeney may publish in the future.

Co-authorship network of co-authors of Michael Sweeney

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Sweeney. A scholar is included among the top collaborators of Michael Sweeney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Sweeney. Michael Sweeney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gilham, Dean, Sylwia Wasiak, Brooke D. Rakai, et al.. (2023). Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment. Biomedicines. 11(6). 1663–1663. 6 indexed citations

Wasiak, Sylwia, Li Fu, Dean Gilham, et al.. (2023). The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activationin vitroand in a mouse model of systemic inflammation. Translational Neuroscience. 14(1). 20220332–20220332. 1 indexed citations

Fu, Li, Dean Gilham, Stephanie C. Stotz, et al.. (2023). Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. International Immunopharmacology. 117. 109929–109929. 2 indexed citations

Tóth, Peter P., Gregory G. Schwartz, Stephen J. Nicholls, et al.. (2022). Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease. SHILAP Revista de lepidopterología. 11. 100372–100372. 7 indexed citations

Wasiak, Sylwia, Laura Tsujikawa, Dean Gilham, et al.. (2022). Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. Atherosclerosis. 364. 10–19. 12 indexed citations

Cummings, Jeffrey L., Gregory G. Schwartz, Stephen J. Nicholls, et al.. (2021). Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. Journal of Alzheimer s Disease. 83(4). 1703–1715. 21 indexed citations

Nicholls, Stephen J., Gregory G. Schwartz, Kevin A. Buhr, et al.. (2021). Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovascular Diabetology. 20(1). 13–13. 56 indexed citations

Schwartz, Gregory G., Stephen J. Nicholls, Peter P. Tóth, et al.. (2021). Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovascular Diabetology. 20(1). 125–125. 16 indexed citations

Sweeney, Michael, Stephen J. Nicholls, Kausik K. Ray, et al.. (2020). THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL. Journal of the American College of Cardiology. 75(11). 168–168. 1 indexed citations

10.

Wasiak, Sylwia, Kim E. Dzobo, Brooke D. Rakai, et al.. (2020). BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. Clinical Epigenetics. 12(1). 166–166. 31 indexed citations

11.

Kalantar‐Zadeh, Kamyar, Gregory G. Schwartz, Kevin A. Buhr, et al.. (2020). Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with CKD, Diabetes, and Recent Acute Coronary Syndrome: Results from the BETonMACE Trial. Journal of the American Society of Nephrology. 31(10S). 42–42. 1 indexed citations

12.

Ray, Kausik K., Stephen J. Nicholls, Kevin A. Buhr, et al.. (2020). Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. JAMA. 323(16). 1565–1565. 112 indexed citations

13.

Wasiak, Sylwia, Dean Gilham, Christopher Halliday, et al.. (2019). Abstract 671: Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients. Arteriosclerosis Thrombosis and Vascular Biology. 1 indexed citations

14.

Tsujikawa, Laura, Li Fu, Brooke D. Rakai, et al.. (2019). APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS. Journal of the American College of Cardiology. 73(9). 2063–2063. 1 indexed citations

15.

Haarhaus, Mathias, Kausik K. Ray, Stephen J. Nicholls, et al.. (2019). Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 290. 59–65. 31 indexed citations

16.

Shishikura, Daisuke, Yu Kataoka, Satoshi Honda, et al.. (2018). The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial. American Journal of Cardiovascular Drugs. 19(1). 49–57. 32 indexed citations

17.

Wasiak, Sylwia, Laura Tsujikawa, Christopher Halliday, et al.. (2017). Benefit of Apabetalone on Plasma Proteins in Renal Disease. Kidney International Reports. 3(3). 711–721. 32 indexed citations

18.

Wong, Norman C.W., Ewelina Kulikowski, Cyrus Calosing, et al.. (2017). APABETALONE (RVX-208) LOWERS CARDIOVASCULAR DISEASE (CVD) IN DIABETES MELLITUS BY A MECHANISM INVOLVING MICROBIOME MEDIATED ACTIVITY ON THE COMPLEMENT PATHWAY. Journal of the American College of Cardiology. 69(11). 2009–2009. 1 indexed citations

19.

Wasiak, Sylwia, Dean Gilham, Laura Tsujikawa, et al.. (2016). Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes. Data in Brief. 8. 1280–1288. 15 indexed citations

20.

Gilham, Dean, Sylwia Wasiak, Laura Tsujikawa, et al.. (2016). RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 247. 48–57. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact